AST/ALT Ratio Calculator
Calculate De Ritis Ratio for Liver Health Assessment
Your De Ritis Ratio
What is the AST/ALT Ratio?
The AST/ALT ratio, also known as the De Ritis ratio, measures the relationship between two liver enzymes: aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Named after Fernando De Ritis who described it in 1957, this ratio serves as a diagnostic marker for various liver conditions including hepatitis, cirrhosis, and fatty liver disease.
Both enzymes are released into the bloodstream when liver cells are damaged or die. AST is found in both the cytoplasm and mitochondria of liver cells, while ALT exists primarily in the cytoplasm. This difference in cellular location explains why certain liver conditions produce distinct ratio patterns.
Calculation Formula
Example: If AST = 50 U/L and ALT = 40 U/L, then Ratio = 50 ÷ 40 = 1.25
Clinical Interpretation Ranges
The AST/ALT ratio provides valuable diagnostic information when interpreted alongside absolute enzyme levels and clinical presentation.
| Ratio Range | Clinical Significance | Associated Conditions |
|---|---|---|
| < 1.0 | ALT predominance | Acute viral hepatitis, NAFLD, drug-induced hepatitis, early liver damage |
| 1.0 – 1.5 | Borderline elevation | Chronic hepatitis B or C, early alcoholic liver disease, developing fibrosis |
| 1.5 – 2.0 | Moderate elevation | Alcohol abuse, chronic liver disease, fibrosis risk |
| ≥ 2.0 | High elevation | Alcoholic hepatitis (80% sensitive), cirrhosis, Wilson’s disease |
| > 3.0 | Very high elevation | Acute alcoholic hepatitis, fulminant hepatitis, non-hepatic causes |
| > 5.0 | Extremely high | Extrahepatic tissue damage, rhabdomyolysis, hemolysis |
Normal Enzyme Ranges
Reference ranges for liver enzymes vary between laboratories and depend on factors including age, gender, and methodology used.
| Enzyme | Normal Range (Adults) | Gender Variations |
|---|---|---|
| AST | 8-40 U/L | Typically 10-40 U/L, slightly higher in men |
| ALT | 7-56 U/L | Men: <30 U/L; Women: <20 U/L (strict criteria) |
| AST/ALT Ratio | 0.8-1.3 | Women: up to 1.7; Men: up to 1.3 |
Age-Related Variations
- Neonates typically show AST/ALT ratio > 3.0, normalizing below 2.0 by day 5
- Children maintain ratios between 1.5-2.0 during normal development
- Adults generally exhibit ratios around 1.0 in healthy conditions
- Elderly patients may show slightly elevated ratios due to nutritional factors
Common Liver Conditions
Alcoholic Hepatitis
AST/ALT ratio typically ≥ 2.0. In 92% of patients with alcoholic liver disease, the ratio exceeds 1.0, and in 70% it exceeds 2.0. Mitochondrial AST is preferentially released due to alcohol-induced mitochondrial damage.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Ratio usually < 1.0, typically ranging from 0.3 to 0.8. ALT elevation is more prominent than AST in metabolic liver disease, making the ratio a key differentiator from alcoholic causes.
Acute Viral Hepatitis
Ratio typically 0.5-0.7 in resolving cases. However, ratios ≥ 2.0 may indicate fulminant hepatitis with poor prognosis, requiring immediate medical attention.
Cirrhosis
Ratio typically > 1.0 as fibrosis progresses. In chronic hepatitis B or C, ratios above 1.0 correlate with fibrosis development and predict progression to end-stage liver disease.
Drug-Induced Hepatitis
Variable patterns depending on the drug mechanism. Mitochondrial toxins produce higher AST/ALT ratios, while cytoplasmic damage produces ratios < 1.0.
Rhabdomyolysis
Very high ratios (> 3.0) due to muscle AST release. Creatine kinase levels are markedly elevated. The ratio decreases over days as AST clears faster than ALT.
Factors Affecting the Ratio
Enzyme Half-Life Dynamics
The ratio reflects the time course of liver injury due to different clearance rates. AST has a serum half-life of 18 hours, while ALT persists for 36 hours. This explains why acute conditions initially show high ratios that decrease during recovery.
Cellular Distribution
Liver cells contain AST and ALT in a 2.5:1 ratio. However, AST clearance by liver sinusoidal cells occurs twice as fast as ALT, resulting in approximately equal serum levels in healthy individuals.
Vitamin B6 Deficiency
Both enzymes require pyridoxal phosphate (vitamin B6) as a cofactor. Deficiency may cause falsely low values, particularly affecting AST more than ALT. This is especially relevant in alcoholics, elderly patients, and those with malnutrition.
Mitochondrial Damage
Severe hepatocellular injury releases mitochondrial AST, which comprises approximately 80% of liver AST activity. Conditions causing mitochondrial damage preferentially elevate AST, increasing the ratio.
Clinical Applications
Differentiating Liver Disease Etiology
The ratio helps distinguish between alcoholic and non-alcoholic causes of liver damage. While not definitive alone, it provides valuable diagnostic clues when combined with clinical history and additional testing.
Prognostic Indicator
In chronic hepatitis C, ratios above 1.16 predict poor survival and correlate with Child-Pugh and MELD scores. In chronic hepatitis B, ratios above 1.0 without cirrhosis suggest progressive fibrosis.
Monitoring Disease Progression
Serial measurements track liver disease evolution. Rising ratios in chronic conditions may indicate developing cirrhosis or increased fibrosis, warranting closer monitoring or treatment adjustment.
Screening for Complications
The ratio helps identify patients at risk for hepatocellular carcinoma, variceal bleeding, and hepatic decompensation when combined with other indices like APRI and FIB-4.
| Clinical Scenario | Typical AST Level | Typical ALT Level | Expected Ratio |
|---|---|---|---|
| Healthy adult | 10-30 U/L | 10-30 U/L | 0.8-1.3 |
| NAFLD mild | 30-80 U/L | 50-150 U/L | 0.3-0.8 |
| Acute viral hepatitis | 200-1000 U/L | 300-1500 U/L | 0.5-0.7 |
| Alcoholic hepatitis (active) | 150-400 U/L | 50-150 U/L | 2.0-5.0 |
| Cirrhosis (established) | 80-200 U/L | 60-150 U/L | 1.2-2.5 |
| Acute muscle injury | 500-2000 U/L | 100-400 U/L | 3.0-8.0 |
Liver Enzyme Functions
Aspartate Aminotransferase (AST)
AST catalyzes the transfer of amino groups between aspartate and α-ketoglutarate, producing oxaloacetate and glutamate. This reaction is crucial for the malate-aspartate shuttle, which transfers reducing equivalents from cytoplasmic NADH into mitochondria for oxidative phosphorylation.
AST is non-specific to the liver and is found in multiple tissues including heart, skeletal muscle, kidneys, brain, pancreas, and red blood cells. This widespread distribution means isolated AST elevation requires consideration of non-hepatic sources.
Alanine Aminotransferase (ALT)
ALT catalyzes the reversible transfer of amino groups between alanine and α-ketoglutarate, forming pyruvate and glutamate. This enzyme plays a key role in the glucose-alanine cycle, allowing muscles to eliminate nitrogen while replenishing glucose via gluconeogenesis in the liver.
ALT is more liver-specific than AST, though it can be found in kidneys, heart, and skeletal muscle at lower concentrations. Elevated ALT more reliably indicates hepatocellular injury, making it a preferred screening test for liver disease.
Metabolic Syndrome and Liver Health
The metabolic syndrome components—central obesity, hyperglycemia, low HDL cholesterol, hypertriglyceridemia, and hypertension—strongly correlate with elevated liver enzymes and altered AST/ALT ratios.
Insulin Resistance Connection
Insulin resistance drives hepatic lipogenesis, particularly through increased dietary fructose and glucose conversion to triglycerides. Fasting insulin levels and insulin resistance markers associate with elevated ALT independent of body mass index, suggesting metabolic dysfunction precedes overt fatty liver.
Cardiovascular Risk
Patients with NAFLD have higher mortality rates than the general population and face increased cardiovascular disease risk. The AST/ALT ratio serves as a marker not only for liver health but also for overall metabolic dysfunction.
Progression Prediction
While fatty liver with normal transaminases is often benign, elevated ALT predicts progression to metabolic syndrome. Both AST and ALT elevation predict diabetes development, with ALT being more sensitive for early metabolic changes.
When to Seek Medical Attention
- Persistent elevation of either AST or ALT above normal ranges
- AST/ALT ratio above 2.0, especially with known alcohol consumption
- Symptoms including jaundice (yellowing of skin or eyes), dark urine, or pale stools
- Abdominal pain, swelling, or unexplained fatigue
- Ratio changes from previously stable values
- Elevated enzymes accompanied by fever, nausea, or vomiting
- Known liver disease with ratio trending upward over time
- Medication changes that could affect liver function
Frequently Asked Questions
Why is my AST/ALT ratio important if both values are normal?
When both enzymes are within normal ranges, the ratio has limited clinical significance. The ratio becomes diagnostically valuable when at least one enzyme is elevated, as it helps identify the underlying cause and severity of liver dysfunction.
Can exercise affect my AST/ALT ratio?
Yes. Intense exercise, particularly weightlifting, can elevate AST to 100-1000 U/L and ALT to 50-200 U/L, raising the ratio to approximately 4:1 for up to one week following exercise. Muscle-derived AST causes this temporary elevation.
How often should I check my AST/ALT ratio?
Frequency depends on your condition. Healthy individuals typically need testing every 1-2 years during routine checkups. Those with chronic liver disease, diabetes, or metabolic syndrome may require testing every 3-6 months. Follow your physician’s recommendations.
What does a ratio below 0.5 indicate?
Ratios significantly below 1.0 suggest ALT predominance, typically seen in early-stage viral hepatitis, non-alcoholic fatty liver disease, or drug-induced liver injury. This pattern indicates primarily cytoplasmic hepatocyte damage rather than mitochondrial injury.
Can medications alter my AST/ALT ratio?
Many medications can affect liver enzymes and their ratio. Statins, antibiotics, NSAIDs, and acetaminophen may cause hepatotoxicity. Some drugs damage mitochondria, preferentially elevating AST and increasing the ratio. Always inform your doctor of all medications you take.
Is the AST/ALT ratio the same as SGOT/SGPT ratio?
Yes, they are identical. AST is also called SGOT (serum glutamic-oxaloacetic transaminase), and ALT is also called SGPT (serum glutamic-pyruvic transaminase). The naming conventions vary by region and laboratory, but the ratio calculation remains the same.
What is the APRI score and how does it relate to AST/ALT ratio?
The AST to Platelet Ratio Index (APRI) uses AST level and platelet count to assess liver fibrosis. While it incorporates AST, it’s distinct from the AST/ALT ratio. APRI is calculated as: (AST/upper limit of normal) × 100 / platelet count. Both indices help evaluate liver disease severity.
Does the ratio change after stopping alcohol consumption?
Yes. Due to AST’s shorter half-life (18 hours) versus ALT (36 hours), the ratio decreases within days after alcohol cessation. Elevated ratios in alcoholic hepatitis often reflect recent exposure; chronic drinkers without recent intake may show ratios below 2.0.
References
- De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2:70-4.
- Botros M, Sikaris KA. The De Ritis Ratio: The Test of Time. Clin Biochem Rev. 2013 Nov;34(3):117-130. PMID: 24353357; PMCID: PMC3866949.
- Nyblom H, Berggren U, Balldin J, et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004;39(4):336-339.
- Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-379.
- Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018-1022.
- Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10.
- American Association for the Study of Liver Diseases. Management of Hepatitis C: 2002 Update. Available at: https://www.aasld.org
- National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
- Williams ALB, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology. 1988;95(3):734-739.
- Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93(1):44-48.